Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: Controlled study

Clinical Infectious Diseases

Volumn 26, Issue 1, 1998, Pages 56-58

  Soto, J ^a   Fuya, P ^b   Herrera, R ^b   Berman, J ^b  

^a UNIVERSIDAD MILITAR NUEVA GRANADA   (Colombia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MEGLUMINE ANTIMONATE; METHYLBENZETHONIUM CHLORIDE; PAROMOMYCIN;

ARTICLE; COLOMBIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAMUSCULAR DRUG ADMINISTRATION; LEISHMANIA BRAZILIENSIS; LEISHMANIASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SKIN INFECTION; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0031939452     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/516267     Document Type: Article

References (4)

1. Soto J, Hernandez N, Mejia H, Grogl M, Herman J. Successful treatment of New World cutaneous leishmaniasis with a combination of topical paromomycin/methylbenzethonium chloride and injectable meglumine antimonate. Clin Infect Dis 1995; 20:47-51.
2. Krause G, Kroeger A. Topical treatment of American cutaneous leishmaniasis with paromomycin and methylbenzethonium chloride: a clinical study under field conditions in Ecuador. Trans R Soc Trop Med Hyg 1994; 88: 92-4.
3. El-On J, Livshin R, Evan-Paz Z, Hamburger D, Weinrauch L. Topical treatment of cutaneous leishmaniasis. J Invest Dermatol 1986;87:284-8.
4. El-On J, Halevy S, Grunwald MH, Weinrauch L. Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: a double-blind control study. J Am Acad Dermatol 1992; 27:227-31.